Sanofi (SNY) said Thursday it plans to purchase Dren Bio's experimental autoimmune treatment DR-0201 for $600 million.
The deal, which is expected to close in Q2, also includes up to $1.3 billion in milestone-based payments tied to development progress and potential product launches, the company said.
DR-0201 is a bispecific antibody meant to engage myeloid cells and remove B cells, a mechanism believed to help reset the immune system in hard-to-treat autoimmune disorders.
The drug is currently being tested in two phase 1 trials and has shown early signals of effectiveness in both lab and clinical research, Sanofi said.
The company's shares were down almost 0.5% in recent Thursday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。